Sino Biopharmaceutical to Present Phase II Data for Garsorasib at AACR 2024
Sino Biopharmaceutical Ltd. (HKG: 1177) announced that it will present the results of a Phase...
Cancer
Roche Secures CE Mark for Ventana HER2 Test, Enhancing Access to AstraZeneca’s Enhertu
Roche (SWX: ROG), based in Switzerland, has received CE marking from the European Commission (EC)...
Jiangsu Hengrui Secures NMPA Approval for Clinical Study of SHR-A2102 and SHR-8068 in Advanced Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received approval from the National Medical Products...
Merck Sharp & Dohme Acquires Abceutics for Next-Generation ADC Technology
Global healthcare leader Merck, Sharp & Dohme (MSD) (NYSE: MRK) has secured a strategic acquisition...
Simcere Pharmaceutical’s SIM0500 Earns FDA Fast-Track Designation for Multiple Myeloma
Simcere Pharmaceutical Group (HKG: 2096), a leading China-based pharmaceutical company, has announced that its trispecific...
Roche’s Inavolisib Earns Priority Review Status in China for PIK3CA-Mutated Breast Cancer
Swiss pharmaceutical giant Roche (SWX: ROG) has received priority review status from China’s Center for...
Sichuan Biokin Pharmaceuticals Initiates Phase III Trial for BL-M05D1 in Esophageal Cancer
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the commencement of patient enrollment in...
Jiangsu Hengrui Pharmaceuticals Gains NMPA Approval for HRS-4642 Clinical Trial in KRAS G12D Mutated Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...
Alphamab Oncology’s JSKN003 Demonstrates Promising Results in Phase I HER2-Targeted Solid Tumor Study
Alphamab Oncology (HKG: 9966) presented compelling data from a Phase I clinical trial of its...
Beijing Aosaikang Pharmaceuticals Achieves Clinical Milestone for c-MET Inhibitor ASKC202
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced the presentation of promising data from...
Transcenta Holdings Ltd Collaborates with Agilent Technologies on Companion Diagnostic for Osemitamab
China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced a strategic agreement with Agilent...
CStone Pharmaceuticals Submits New Drug Application for Gavreto in China, Eyes Local Manufacturing
CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has submitted a market...
Jiangsu Hengrui Pharmaceuticals Secures IND Approvals for Two Drug Candidates from China’s NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received Investigational New Drug (IND) approvals from...
Adicon Launches GuardantOMNI Test to Advance Tumor Therapy Development in China
Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory service provider, has announced the...
Merck Collaborates with Caris Life Sciences to Develop First-in-Class Antibody-Drug Conjugates
German pharmaceutical giant Merck (ETR: MRK) has entered into a strategic collaboration with Caris Life...
AstraZeneca’s Imfinzi Achieves Positive Results in Late-Stage Trial for Small Cell Lung Cancer
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that a late-stage trial for its...
AstraZeneca and Daiichi Sankyo’s Enhertu Secures FDA Approval for HER2-Positive Solid Tumors
Partners AstraZeneca (AZ; NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have been granted an additional...
Bristol Myers Squibb’s Abecma Receives FDA Approval for Wider Use in Multiple Myeloma Treatment
The US Food and Drug Administration (FDA) has granted an indication extension for Bristol Myers...
Dizal Pharmaceutical’s Sunvozertinib Earns FDA Breakthrough Therapy Designation for NSCLC
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a leading Chinese pharmaceutical company, has announced that its...
Sino Biopharmaceutical Partners with Boehringer Ingelheim to Bring Innovative Cancer Therapies to China
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a strategic partnership with Germany’s Boehringer Ingelheim (BI)...